Insider Transactions in Q2 2025 at Verona Pharma PLC (VRNA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
80,000
-18.18%
|
$880,000
$11.53 P/Share
|
|
Jun 16
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+15.38%
|
$160,000
$2.01 P/Share
|
|
Jun 11
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
400,000
-2.94%
|
$4,400,000
$11.4 P/Share
|
|
Jun 11
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400,000
-3.15%
|
$4,400,000
$11.4 P/Share
|
|
May 29
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
208,696
-1.51%
|
$1,878,264
$9.33 P/Share
|
|
May 29
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
204,864
-1.59%
|
$1,843,776
$9.33 P/Share
|
|
May 28
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
157,704
-1.13%
|
$1,419,336
$9.3 P/Share
|
|
May 28
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
162,704
-1.25%
|
$1,464,336
$9.3 P/Share
|
|
May 27
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
33,600
-0.24%
|
$302,400
$9.53 P/Share
|
|
May 27
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,432
-0.25%
|
$291,888
$9.53 P/Share
|
|
May 20
2025
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
160,000
-68.25%
|
$1,440,000
$9.39 P/Share
|
|
May 20
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
160,000
+40.56%
|
$0
$0.5 P/Share
|
|
May 15
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
80,000
-18.18%
|
$640,000
$8.57 P/Share
|
|
May 15
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+15.38%
|
$160,000
$2.11 P/Share
|
|
May 14
2025
|
Christina Ackermann Director |
SELL
Open market or private sale
|
Direct |
40,000
-48.85%
|
$320,000
$8.44 P/Share
|
|
May 14
2025
|
Christina Ackermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+32.82%
|
$40,000
$1.93 P/Share
|
|
May 06
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
114,984
-4.32%
|
$919,872
$8.82 P/Share
|
|
May 02
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
400,000
-2.78%
|
$3,600,000
$9.09 P/Share
|
|
May 02
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400,000
-2.97%
|
$3,600,000
$9.09 P/Share
|
|
May 01
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
187,008
-0.65%
|
$1,496,064
$8.95 P/Share
|
|
May 01
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+1.36%
|
-
|
|
May 01
2025
|
David R Ebsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
140,000
+8.66%
|
$140,000
$1.93 P/Share
|
|
May 01
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
187,008
-0.69%
|
$1,496,064
$8.95 P/Share
|
|
May 01
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+1.45%
|
-
|
|
May 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,200
-0.92%
|
$393,600
$8.95 P/Share
|
|
May 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.83%
|
-
|
|
Apr 29
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
90,360
-0.67%
|
$722,880
$8.98 P/Share
|
|
Apr 29
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.66%
|
-
|
|
Apr 29
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
34,384
-1.28%
|
$275,072
$8.98 P/Share
|
|
Apr 29
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+3.09%
|
-
|
|
Apr 29
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
90,360
-0.62%
|
$722,880
$8.98 P/Share
|
|
Apr 29
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.56%
|
-
|
|
Apr 29
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
26,072
-6.75%
|
$208,576
$8.98 P/Share
|
|
Apr 29
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+18.23%
|
-
|
|
Apr 29
2025
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
20,000
-11.53%
|
$160,000
$8.92 P/Share
|
|
Apr 29
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+10.13%
|
$20,000
$1.1 P/Share
|